E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10039628 |
E.1.2 | Term | Schizophrenia and other psychotic disorders |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of intranasal OXT in reducing negative symptoms in patients with SZ (as evaluated with PANSS), in association with standard SGA treatment; recruited patients will be aged 18-35 years and will have a disorder duration of no longer than 5 years. |
|
E.2.2 | Secondary objectives of the trial |
To use an Emotional Priming Paradigm (EPP) task to assess pre- and post-treatment change in the patients general cognitive and emotional status. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Outpatients with a diagnosis of Schizophrenia, according to DSM-IV criteria, for at least one year, assessed via SCID-I/P. -A minimum PANSS total score of 55 (indicating moderate severity, due to ongoing AP treatment) at T0 and a score of at least 4 on the PANSS suspiciousness subscale. -A minimum CGI-S score of 4 -Age between 18 and 35 years -A disorder duration of no longer than 5 years -Women of childbearing age must test negative for pregnancy at the time of enrolment - Have at least one family member, or a trusted person, who has daily contact with the patient, and can help him with the management of treatment. All patients must: -be on a therapeutic dose of a SGA (or a maximum 2 SGAs) with no major dose changes for at least 4 weeks. -have the ability to provide informed consent -be able to use a nasal spray -reside in the service catchment area -show evidence of no alcohol or substance abuse/dependence in the last year |
|
E.4 | Principal exclusion criteria |
-Diagnosis of mental retardation (IQ<70 as assessed via Wechsler Adult Intelligence Scale WAIS) -Diagnosis of organic mental disorder -History of no response to treatment with clozapine -Be on a antipsychotic depot therapy -History of hypersensitivity to OXT or vehicle -Alcohol or substance abuse/dependence in the last year -Presence of, or history of clinically significant allergic rhinitis as assessed by the treating clinician -Being pregnant or breastfeeding -Having given birth in the past 6 months or breast-feeding in the past 3 months -Low literacy as indicated by an inability to read and understand the consent form. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The trials primary outcome measure will be the difference in PANSS negative score, as measured at T0 and at 4 and 8 months. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The secondary end-points will be the PANSS total score, the Brief Assessment of Cognitive deficits in Schizophrenics (BACS) score and the Reading the Mind in the Eyes Test (RMET) score changes from T0 to final assessment and changes in EPP task reaction times and accuracy. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |